Cargando…
Adipositas und Typ-2-Diabetes (Update 2023)
The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e.g. bioimpedance analysis (BIA), are...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133053/ https://www.ncbi.nlm.nih.gov/pubmed/37101029 http://dx.doi.org/10.1007/s00508-023-02184-6 |
_version_ | 1785031512317493248 |
---|---|
author | Clodi, Martin Toplak, Hermann Resl, Michael Brix, Johanna Leitner, Deborah Raphaela Harreiter, Jürgen Hoppichler, Friedrich Wascher, Thomas C. Schindler, Karin Ludvik, Bernhard |
author_facet | Clodi, Martin Toplak, Hermann Resl, Michael Brix, Johanna Leitner, Deborah Raphaela Harreiter, Jürgen Hoppichler, Friedrich Wascher, Thomas C. Schindler, Karin Ludvik, Bernhard |
author_sort | Clodi, Martin |
collection | PubMed |
description | The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e.g. bioimpedance analysis (BIA), are recommended. Lifestyle management including nutrition modification and increase in physical activity are important measures for the prevention and treatment of diabetes. Regarding the treatment of type 2 diabetes, body weight is increasingly used as a secondary target parameter. The choice of anti-diabetic treatment and additional concomitant therapies is increasingly influenced by body weight. The importance of modern GLP‑1 agonists and dual GLP‑1 GIP agonists increases since these drugs target obesity and type 2 diabetes. Bariatric surgery is at present indicated with a BMI > 35 kg/m(2) with concomitant risk factors, such as diabetes and can lead at least to partial diabetes remission but has to be incorporated into an appropriate lifelong care concept. |
format | Online Article Text |
id | pubmed-10133053 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-101330532023-04-28 Adipositas und Typ-2-Diabetes (Update 2023) Clodi, Martin Toplak, Hermann Resl, Michael Brix, Johanna Leitner, Deborah Raphaela Harreiter, Jürgen Hoppichler, Friedrich Wascher, Thomas C. Schindler, Karin Ludvik, Bernhard Wien Klin Wochenschr Leitlinien Für Die Praxis The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e.g. bioimpedance analysis (BIA), are recommended. Lifestyle management including nutrition modification and increase in physical activity are important measures for the prevention and treatment of diabetes. Regarding the treatment of type 2 diabetes, body weight is increasingly used as a secondary target parameter. The choice of anti-diabetic treatment and additional concomitant therapies is increasingly influenced by body weight. The importance of modern GLP‑1 agonists and dual GLP‑1 GIP agonists increases since these drugs target obesity and type 2 diabetes. Bariatric surgery is at present indicated with a BMI > 35 kg/m(2) with concomitant risk factors, such as diabetes and can lead at least to partial diabetes remission but has to be incorporated into an appropriate lifelong care concept. Springer Vienna 2023-04-20 2023 /pmc/articles/PMC10133053/ /pubmed/37101029 http://dx.doi.org/10.1007/s00508-023-02184-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Leitlinien Für Die Praxis Clodi, Martin Toplak, Hermann Resl, Michael Brix, Johanna Leitner, Deborah Raphaela Harreiter, Jürgen Hoppichler, Friedrich Wascher, Thomas C. Schindler, Karin Ludvik, Bernhard Adipositas und Typ-2-Diabetes (Update 2023) |
title | Adipositas und Typ-2-Diabetes (Update 2023) |
title_full | Adipositas und Typ-2-Diabetes (Update 2023) |
title_fullStr | Adipositas und Typ-2-Diabetes (Update 2023) |
title_full_unstemmed | Adipositas und Typ-2-Diabetes (Update 2023) |
title_short | Adipositas und Typ-2-Diabetes (Update 2023) |
title_sort | adipositas und typ-2-diabetes (update 2023) |
topic | Leitlinien Für Die Praxis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133053/ https://www.ncbi.nlm.nih.gov/pubmed/37101029 http://dx.doi.org/10.1007/s00508-023-02184-6 |
work_keys_str_mv | AT clodimartin adipositasundtyp2diabetesupdate2023 AT toplakhermann adipositasundtyp2diabetesupdate2023 AT reslmichael adipositasundtyp2diabetesupdate2023 AT brixjohanna adipositasundtyp2diabetesupdate2023 AT leitnerdeborahraphaela adipositasundtyp2diabetesupdate2023 AT harreiterjurgen adipositasundtyp2diabetesupdate2023 AT hoppichlerfriedrich adipositasundtyp2diabetesupdate2023 AT wascherthomasc adipositasundtyp2diabetesupdate2023 AT schindlerkarin adipositasundtyp2diabetesupdate2023 AT ludvikbernhard adipositasundtyp2diabetesupdate2023 |